Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Perceptive Instruments Earn Out Payment

13 Feb 2015 07:00

RNS Number : 8002E
Instem plc
13 February 2015
 



13 February 2015

Instem plc("Instem" or the "Company")

 

Perceptive Instruments Earn Out Payment

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that it has paid in full the performance based earn out of £300,000 in respect of the acquisition of Perceptive Instruments Limited ('Perceptive').

 

Earn Out Payment

As a result of Perceptive achieving all of the specified earn out targets for the period to 21 November 2014, the Vendors have been paid the maximum additional consideration of £300,000 in accordance with the Acquisition Agreement.

 

Background to the Acquisition

Instem acquired Perceptive in November 2013 for a maximum consideration of £1.3m, including the conditional earn out, marking the Company's entrance into the in vitro R&D marketplace.

 

Perceptive is located in Suffolk, UK, and develops, manufactures and supplies software and hardware products for in vitro study data collection and study management in the genetic toxicology, microbiology and immunology markets. Perceptive is the leading technology provider within its niche market and there are few competitors active in the space.

 

Phil Reason, CEO of Instem, said: "The acquisition of Perceptive has been a success, not only in terms of the financial contribution the acquisition has made to date, but also in terms of expanding the Company's offering into the in vitro data collection and study management in the genetic toxicology, microbiology and immunology markets We are looking forward to another strong contribution from this area in 2015 and beyond."

 

For further information, please contact:

Instem plc

Tel: +44 (0) 1785 825 600

Phil Reason, CEO

www.instem.com

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: +44 (0) 20 7496 3000

Richard Lindley

 

Nick Owen

 

 

 

Walbrook PR Ltd

Tel: +44 (0) 20 7933 8780 or

Paul Cornelius

instem@walbrookpr.com

Sam Allen

 

Nick Rome

 

 

 

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutionsfor data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

 

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.

 

To learn more about Instem solutions and its mission, please visit www.instem.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAKAAFSDSEFF
Date   Source Headline
22nd Jan 200812:11 pmRNSAcquisition
22nd Jan 200812:00 pmRNSDisposal
21st Dec 20071:22 pmRNSChange of Year End
22nd Oct 20075:57 pmRNSNotification of Shares
10th Oct 20075:29 pmRNSTrading Statement
27th Sep 200712:43 pmRNSNotification of Shares
7th Sep 20071:25 pmRNSNotification of Shares
31st Aug 20075:10 pmRNSOffer Update
31st Aug 20071:53 pmRNSTotal Voting Rights
28th Aug 20074:58 pmRNSAIM Rule 26
22nd Aug 20077:00 amRNSOffer Update
20th Aug 20072:37 pmRNSInterim Results
7th Aug 20075:41 pmRNSOffer Update
7th Aug 20075:29 pmRNSHolding(s) in Company
2nd Aug 20075:43 pmRNSExercise of options
31st Jul 20074:55 pmRNSExercise of Options
27th Jul 20078:00 amRNSIssue of Equity
24th Jul 20075:09 pmRNSOffer Update
24th Jul 20072:49 pmRNSDirector/PDMR Shareholding
24th Jul 20072:47 pmRNSDirector/PDMR Shareholding
24th Jul 20072:46 pmRNSDirector/PDMR Shareholding
24th Jul 20072:45 pmRNSDirector/PDMR Shareholding
24th Jul 20072:42 pmRNSDirector/PDMR Shareholding
23rd Jul 20073:41 pmRNSHolding(s) in Company
23rd Jul 20071:30 pmRNSAGM Statement
20th Jul 200712:08 pmRNSHolding(s) in Company
10th Jul 20072:13 pmBUSRule 8.3 - International Nuclear Solutions
9th Jul 20073:03 pmBUSRule 8.3 - International Nuclear Solutions
9th Jul 200712:10 pmRNSOffer unconditional
9th Jul 20079:33 amRNSInt Nuclear Solutions
6th Jul 20073:09 pmBUSRule 8.3 - International Nuclear Solutions
5th Jul 20071:51 pmBUSRule 8.3 - International Nuclear Solutions
4th Jul 200712:38 pmBUSRule 8.3 - International Nuclear Solutions
3rd Jul 20072:25 pmBUSRule 8.3 - International Nuclear Solutions
29th Jun 20073:05 pmRNSHolding(s) in Company
28th Jun 200711:44 amRNSHolding(s) in Company
28th Jun 20079:24 amRNSRule 8.1- Intnl Nuclear Sol.
27th Jun 20073:34 pmBUSRule 8.3 - International Nuclear Solutions
25th Jun 20073:18 pmRNSRule 8.1- (Intl Nuclear Sol)
25th Jun 20079:01 amRNSHolding(s) in Company
21st Jun 20072:52 pmBUSRule 8.3 - International Nuclear Solution
21st Jun 20072:34 pmRNSRule 8.3- Int'l Nuclear Sol
20th Jun 20073:19 pmBUSRule 8.3 - INTERNATIONAL NUCLEAR SOLUTIONS
20th Jun 20071:35 pmRNSRule 8.3- Int'l Nuclear Sol.
20th Jun 200710:16 amRNSRule 8.3- Intl Nuclear Sols
20th Jun 200710:02 amRNSRule 8.1- Intl Nuclear Sol
19th Jun 20077:03 amRNSOffer for INS
15th Jun 200711:53 amRNSRule 8.3- Intnl Nuclear
12th Jun 200711:08 amRNSRule 8.3- Intnl Nuclear Sol.
29th May 20073:18 pmBUSRule 8.3 - International Nuclear Solution

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.